Stryker stock gains as Q3 growth meets a lower 2026 outlook
Published on 11/03/2026 at 17:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSStryker Q3 outlook shifts
- Third-quarter sales increased 7.7 percent, while adjusted earnings per share rose 10.3 percent.
- Management lowered its 2026 organic sales-growth and adjusted earnings guidance ranges.
- MedSurg and Neurotechnology grew faster than Orthopaedics in the quarter.
Stryker reported third-quarter results on Thursday, October 29, and lowered its 2026 outlook after performance fell short of management expectations. The update adds a new earnings and guidance assessment to the company's recent market picture.
Growth remained uneven
According to Stryker's GlobeNewswire release, third-quarter net sales rose 7.7 percent year over year to USD 6.52 billion. MedSurg and Neurotechnology sales increased 9.2 percent to USD 3.7 billion, while Orthopaedics grew 5.7 percent to USD 2.9 billion.
Reported net earnings fell 12.3 percent to USD 753 million, and reported diluted earnings per share declined 11.7 percent to USD 1.96. The quarter included a USD 293 million goodwill impairment. On an adjusted basis, net earnings rose 10.1 percent to USD 1.4 billion, adjusted earnings per share increased 10.3 percent to USD 3.52, and adjusted operating margin widened 60 basis points to 26.2 percent.
Lower guidance raises pressure
Stryker now expects 2026 organic sales growth of 6.5 percent to 7.0 percent and adjusted diluted earnings per share of USD 14.80 to USD 14.90. The previous ranges were 8.3 percent to 9.3 percent for organic sales growth and USD 14.95 to USD 15.10 for adjusted earnings per share. Management said the underlying fundamentals remained strong and pointed to solid fourth-quarter performance and momentum heading into 2027.
What changed for investors
Stryker stock traded at 278.20 euros on Lang & Schwarz at 5:09 p.m. CET on Tuesday, November 3, 2.17 percent above the Xetra close of Monday, November 2. The quote was 5.22 percent above the 264.40 euros recorded in the October 30 report, a separate comparison from the Xetra day move.
Investors can follow the real-time quote of Stryker Corp stock separately from the company's U.S. dollar listing.
Stryker Corporation stock facts
- Company: Stryker Corporation
- ISIN: US8636671013
- Ticker: SYK
- Home exchange: NYSE
- Lang & Schwarz quote: 278.20 euros on November 3, 2026, at 5:09 p.m. CET
- Change versus Xetra close: Plus 2.17 percent versus 272.30 euros on November 2, 2026
- Sector: Healthcare
- Industry: Medical devices
The S&P 500 market environment provides the broader backdrop for the U.S.-listed medical-technology company.
More news and analyses on Stryker Corp stock are available for investors.
